Drug Trial Radar · NCT03844217
Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Aug 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Mar 7, 2019
Primary completion
Jul 16, 2019
Study completion Jul 16, 2019
Sponsor
- Lead sponsor
- University Hospital, Basel, SwitzerlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 18, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Model
- Sequential
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study investigates stimulation of the posterior pituitary gland by oral Macimorelin (a ghrelin receptor Agonist) to be a novel diagnostic test in the polyuria-polydipsia syndrome.
Conditions
- Polyuria-polydipsia Syndrome
Interventions
Macimorelin 0.5mg/kg body weightDrug
oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin
Macimorelin 0.75mg/kg body weightDrug
oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Copeptin value (pmol/l), after intake of Macimorelin of 0.5mg/kg body weightTime frame: baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Basel Endocrinology, Diabetes and Metabolism
Basel, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.